Jade Biosciences (JBIO) Operating Expenses (2020 - 2026)

Jade Biosciences' Operating Expenses history runs 7 years deep, the most recent figure standing at $43.4 million for Q1 2026.

• Quarterly Operating Expenses rose 85.79% year-over-year to $43.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.6 million (up 33.53% YoY) and the FY2025 annual result came in at $113.5 million, up 52.21% from the prior year.
• Operating Expenses was $43.4 million for Q1 2026 at Jade Biosciences, up from $35.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $43.4 million in Q1 2026 and bottomed at $11.0 million in Q1 2022.
• A 5-year average of $23.1 million and a median of $22.1 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 296.37% — and 2024, when it declined 29.97%.
• Jade Biosciences' Operating Expenses stood at $15.9 million in 2022, then jumped by 39.2% to $22.1 million in 2023, then soared by 61.05% to $35.5 million in 2024, then declined by 1.57% to $35.0 million in 2025, then advanced by 24.2% to $43.4 million in 2026.
• Business Quant data shows JBIO's Operating Expenses at $43.4 million in Q1 2026, $35.0 million in Q4 2025, and $27.4 million in Q3 2025.